Back to top
January 18, 2018
FDA Review: Clobazam Oral Soluble Film for Treating Lennox-Gastaut Syndrome
Research, Treatments

The U.S. Food and Drug Administration has accepted for review a New Drug Application for clobazam Oral Soluble Film (clobazam OSF) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older. The target date for completion of the FDA review is the third-quarter of 2018.
 
Clobazam OSF is administered using Aquestive's PharmFilm drug delivery technology. Similar in size and thickness to a stamp, Aquestive's PharmFilm dissolves instantly after being placed on the tongue and can be administered without water.

Two multicenter controlled studies were conducted to evaluate the bioequivalence of clobazam OSF with clobazam tablets, a benzodiazepine currently on market, at the same dosage strengths. Based on the studies, clobazam OSF was demonstrated to be bioequivalent to clobazam tablets and have comparable safety.

Learn More

 

Related News

May 12, 2018
Rush is First to Use Microburst Vagus Nerve Stimulation for...

Epilepsy patients who have not responded to standard drug treatments may benefit from a new therapy that delivers high frequency bursts of...

Read More
May 10, 2018
Study: Efficacy and Safety of Ketogenic Diet for Treatment...

This series suggests efficacy and safety of ketogenic diet (KD) for treatment of pediatric convulsive refractory status epilepticus (RSE).

Read More
May 9, 2018
Study: Risk Assessment of In-Hospital Mortality of Patients...

The in-hospital mortality of people with epilepsy increased remarkably with age, and this parameter was predominant in male patients, according...

Read More